Fulgent Genetics, Inc. FLGT

Company Overview

Fulgent Genetics, Inc. is a U.S.-based molecular diagnostics company that develops and provides genetic testing services for clinical, research, and commercial applications. The company operates within the genetic testing, molecular diagnostics, and precision medicine industries, offering next-generation sequencing (NGS)–based tests that support disease diagnosis, carrier screening, oncology profiling, and rare disease identification. Its core revenue is generated from laboratory-developed tests and diagnostic services provided to healthcare providers, hospitals, government agencies, and life sciences organizations.

The company is known for its flexible testing platform, which allows physicians to customize gene panels rather than relying solely on fixed test menus. This adaptability, combined with an integrated laboratory and bioinformatics infrastructure, has been cited as a strategic advantage. Fulgent Genetics was founded in 2011 and grew initially through hereditary disease testing before expanding significantly during the COVID-19 pandemic, when large-scale testing contracts became a major but time-limited revenue driver. Post-pandemic, the company has refocused on long-term growth areas such as oncology, reproductive health, and population-scale genomics.